{
  "id": 5915,
  "text": "DOI: 10.1016/ S0140-6736(17)31607-0.[73] Kitagawa R, Katsumata N, Shibata T, et al.Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase Ⅲ trial JCOG0505[J].",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: DOI: 10.1016/ S0140-6736(17)31607-0.[73] Kitagawa R, Katsumata N, Shibata T, et al.Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase Ⅲ trial JCOG0505[J].\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在治疗转移性或复发性宫颈癌方面，一项随机开放的III期临床试验比较了使用紫杉醇联合卡铂与紫杉醇联合顺铂的效果。研究结果显示，紫杉醇联合卡铂方案在无进展生存期和总体生存率方面与紫杉醇联合顺铂方案类似。同时，紫杉醇联合卡铂的方案显示了更好的耐受性，患者经历较少的副作用。这表明在转移性或复发性宫颈癌的治疗中，紫杉醇联合卡铂可能是一个更安全的选择，同时提供了相Comparable的疗效。",
  "query": "在治疗转移性或复发性宫颈癌时，使用紫杉醇联合卡铂与使用紫杉醇联合顺铂相比，有哪些临床试验结果？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在治疗转移性或复发性宫颈癌时，使用紫杉醇联合卡铂与使用紫杉醇联合顺铂相比，有哪些临床试验结果？\n\n<reference text>: DOI: 10.1016/ S0140-6736(17)31607-0.[73] Kitagawa R, Katsumata N, Shibata T, et al.Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase Ⅲ trial JCOG0505[J].\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在治疗转移性或复发性宫颈癌方面，一项随机开放的III期临床试验比较了使用紫杉醇联合卡铂与紫杉醇联合顺铂的效果。研究结果显示，紫杉醇联合卡铂方案在无进展生存期和总体生存率方面与紫杉醇联合顺铂方案类似。同时，紫杉醇联合卡铂的方案显示了更好的耐受性，患者经历较少的副作用。这表明在转移性或复发性宫颈癌的治疗中，紫杉醇联合卡铂可能是一个更安全的选择，同时提供了相Comparable的疗效。"
}